Recruiting PHASE1 INTERVENTIONAL 2-arm
NCT07096869
Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) in Breast Cancer Patients
A Randomized, Open-Label, Two-Period, Crossover Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) and Abraxane® in Breast Cancer Patients
Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Conditions
Bioequivalence
Interventions
Abraxane® Paclitaxel protein-bound particles for injectable suspension (albumin-bound)
Updated 1 time since 2025 Last updated: Jul 24, 2025 Started: Jun 26, 2025 Primary completion: Dec 31, 2025 Completion: Feb 25, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE1 trial investigates Bioequivalence and is currently actively recruiting participants. CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. leads this study, which shows 1 recorded version since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
1 version recorded Recruiting — PHASE1
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Data source: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .